Article
Verteporfin launched into Japanese market
New York-Japanese patients have access to the only treatment for some forms of wet age-related macular degeneration (AMD) with the launch of verteporfin (Visudyne, QLT PhotoTherapeutics/Novartis Ophthalmics) in Japan.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Related Videos
Related Content
